查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1889212

2032年解剖病理學市場預測：按產品、技術、應用、最終用戶和地區分類的全球分析

Anatomic Pathology Market Forecasts to 2032 - Global Analysis By Product (Instruments, Consumables, and Services), Technique, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2025 年，全球解剖病理學市場規模將達到 387.8 億美元，到 2032 年將達到 841.4 億美元，預測期內複合年成長率為 11.7%。

解剖病理學是一門醫學專科，它透過檢查從人體取出的組織、器官和細胞來診斷疾病。解剖病理學家運用宏觀檢查、微觀分析和先進的實驗室技術，識別腫瘤、感染疾病和結構改變等異常情況。解剖病理學家在指南各種醫學學科的臨床決策方面發揮著至關重要的作用，他們提供精準的診斷資訊，支持患者管理、治療方案製定和疾病監測。

根據世界衛生組織（世衛組織）估計，2022 年全球將新增 2,000 萬例癌症病例，並有 970 萬人死於癌症。

擴大個人化醫療的普及範圍

隨著治療方案越來越注重個人化，臨床醫師越來越依賴精準的組織分析來指南決策。分子病理學和基於生物標記的檢測技術正在不斷發展，提高了治療選擇的精確度。數位病理學與人工智慧工具的融合，使得診斷更加快速、深入。醫療機構正加大對專業病理服務的投入，以支持個人化治療策略。這種向精準醫療的轉變預計將持續推動市場的長期成長。

熟練病理學家和技術人員短缺

由於工作量增加和專科醫生短缺，許多醫療機構都面臨延誤問題。隨著診斷程序日益複雜，對專業技能的需求也更加迫切。培訓計畫的擴展速度未能跟上診斷量的成長，這會導致檢測結果的周轉時間延長，並影響臨床決策。這種人才短缺問題對全球醫療機構的運作構成了持續的挑戰。

對伴隨診斷（CDx）的需求不斷成長

標靶治療的日益普及加速了病理解剖學領域對伴隨診斷的需求。這些檢測能夠根據患者的生物標記，幫助確定是否適合接受特定藥物治療。不斷成長的腫瘤藥物研發管線進一步推動了伴隨診斷在臨床工作流程中的整合。組織分析技術的進步提高了預測性檢測的準確性。全球市場對伴隨診斷相關療法的監管核准也不斷擴大。這種日益成長的需求為病理服務提供者和診斷研發公司帶來了巨大的機會。

替代產品和技術的威脅

由於液態生物檢體具有非侵入性和快速出結果的優點，因此備受關注。影像技術的進步也對傳統的組織檢測提出了挑戰。一些醫療機構可能會轉向這些替代方法以提高診斷效率。科技的快速創新有可能進一步降低對傳統病理學方法的依賴。這種競爭環境可能會限制那些未能適應發展趨勢的醫療機構的發展。

新冠疫情的影響：

新冠疫情擾亂了許多實驗室的檢查室流程，導致擇期診斷檢測延誤。病理科面臨病例量減少和常規檢測延誤的雙重困境。然而，這場危機加速了數位化病理和遠距離診斷審核模式的普及。檢查室紛紛投資自動化和雲端基礎系統，以維持服務的連續性。疫情後的戰略重點在於建立更強大的基礎設施、提高人員配備的柔軟性以及運用技術手段進行診斷。

預計在預測期內，服務業細分市場將佔據最大的市場佔有率。

預計在預測期內，服務領域將佔據最大的市場佔有率，這主要得益於診斷檢測外包給專業病理檢查室的趨勢日益成長。醫療機構依賴這些服務進行先進的分子和解剖病理分析。服務供應商提供全面的檢測流程，無需醫院投資昂貴的設備。數位病理和快速報告功能也進一步推動了市場需求。

預計在預測期內，醫院和門診手術中心（ASC）板塊的複合年成長率將最高。

預計在預測期內，醫院和門診手術中心（ASC）領域將實現最高成長率，因為患者入院人數的增加和手術量的擴大推動了對院內病理支持的需求。許多醫療機構正在採用數位化病理平台來加速診斷決策。對現代化檢查室基礎設施的投資正在幫助醫院減少對外部診斷中心的依賴。人工智慧工具的應用正在提高工作流程的效率和準確性。

佔比最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其強大的醫療基礎設施和龐大的診斷檢測量。該地區受益於數位病理學和人工智慧驅動的診斷工具的早期應用。對癌症研究和生物標記開發的大規模投資進一步推動了市場成長。有利的報銷政策也促進了先進病理服務的普及。

複合年成長率最高的地區：

預計亞太地區在預測期內將實現最高的複合年成長率，這主要得益於醫療保健體系的擴展和人們對疾病早期診斷意識的提高。中國和印度等國家正大力投資現代檢測技術。癌症發生率的上升正在加速先進病理服務的普及。公私部門的合作正在提高新興市場的診斷可及性。

免費客製化服務：

購買此報告的客戶可享有以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，提供主要國家的市場估算和預測，以及複合年成長率（註：可行性需確認）。
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 摘要
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球解剖病理學市場（依產品分類）

  • 裝置
    • 切片機
    • 染色設備
    • 組織處理系統
  • 消耗品
    • 試劑
    • 幻燈片盒
    • 成套工具
  • 服務
    • 解剖病理服務
    • 免疫組織化學服務
    • 細胞病理服務
    • 數位病理服務

6. 全球解剖病理學市場（依技術分類）

  • 組織學
  • 血液凝固檢驗
  • 免疫組織化學（IHC）
  • 血清學/免疫學
  • 分子病理學
  • 一般血液檢查

7. 全球解剖病理學市場（按應用分類）

  • 疾病診斷
    • 腫瘤學
    • 感染疾病
    • 慢性病
  • 藥物發現與開發
  • 其他用途

8. 全球解剖病理學市場（依最終用戶分類）

  • 醫院和門診手術中心（ASC）
  • 臨床和診斷檢查室
  • 研究所
  • 血庫
  • 其他最終用戶

9. 全球解剖病理學市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章 企業概況

  • Roche Diagnostics
  • Becton, Dickinson and Company（BD）
  • Thermo Fisher Scientific
  • Hologic Inc.
  • Agilent Technologies
  • PerkinElmer
  • Danaher Corporation
  • Abbott Laboratories
  • Sakura Finetek Japan
  • Merck KGaA
  • BioGenex Laboratories
  • Cardinal Health
  • Quest Diagnostics
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories
Product Code: SMRC32672

According to Stratistics MRC, the Global Anatomic Pathology Market is accounted for $38.78 billion in 2025 and is expected to reach $84.14 billion by 2032 growing at a CAGR of 11.7% during the forecast period. Anatomic pathology is a medical specialty focused on diagnosing diseases by examining tissues, organs, and cells removed from the body. It involves techniques such as gross examination, microscopic analysis, and advanced lab testing to identify abnormalities, including tumors, infections, and structural changes. Anatomic pathologists play a crucial role in guiding clinical decisions by providing precise diagnostic information that supports patient management, treatment planning, and disease monitoring across various medical fields.

According to the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths worldwide.

Market Dynamics:

Driver:

Growing adoption of personalized medicine

As treatments become more tailored to individual patient profiles, clinicians rely heavily on precise tissue analysis to guide decision-making. Molecular pathology and biomarker-driven testing are expanding, enhancing the accuracy of therapeutic selections. Integration of digital pathology and AI-based tools is enabling faster and more detailed diagnostic insights. Healthcare providers are increasingly investing in specialized pathology services to support individualized treatment strategies. This shift toward precision care is expected to continue strengthening the market's long-term growth.

Restraint:

Shortage of skilled pathologists and technicians

Many healthcare facilities face delays due to high workloads and limited expert availability. The growing complexity of diagnostic procedures further increases the demand for specialized skill sets. Training programs are not expanding quickly enough to meet rising diagnostic volumes. As a result, turnaround times may lengthen, affecting clinical decision-making. This workforce gap continues to pose operational challenges for institutions worldwide.

Opportunity:

Rising demand for companion diagnostics (CDx)

Increasing adoption of targeted therapies is accelerating the need for companion diagnostics in anatomic pathology. These tests help determine the suitability of specific drugs based on individual patient biomarkers. Growth in oncology pipelines is further driving CDx integration into clinical workflows. Advancements in tissue profiling technologies are enhancing the accuracy of predictive testing. Regulatory approvals for CDx-linked treatments are expanding across global markets. This rising demand is opening significant opportunities for pathology providers and diagnostic developers.

Threat:

Threat of substitute products/techniques

Liquid biopsy methods are gaining attention due to their non-invasive nature and faster turnaround times. Advancements in imaging-based diagnostics are also challenging traditional tissue examination. Some healthcare providers may shift toward these substitutes to streamline diagnostics. Rapid technological innovations could further reduce reliance on conventional pathology approaches. This competitive environment may limit growth for providers who do not adapt to evolving trends.

Covid-19 Impact:

The COVID-19 pandemic disrupted laboratory workflows and slowed elective diagnostic procedures in many facilities. Pathology departments faced reduced case volumes and delays in routine testing. However, the crisis accelerated digital pathology adoption and remote diagnostic review models. Laboratories invested in automation and cloud-based systems to maintain service continuity. Post-pandemic strategies now emphasize stronger infrastructure, workforce flexibility, and technology-enabled diagnostics.

The services segment is expected to be the largest during the forecast period

The services segment is expected to account for the largest market share during the forecast period, driven by rising outsourcing of diagnostic testing to specialized pathology laboratories. Healthcare providers rely on these services for advanced molecular and histopathological analyses. Service providers offer comprehensive testing workflows without requiring hospitals to invest in costly equipment. Their capabilities in digital pathology and rapid reporting further drive demand.

The hospitals & ambulatory surgical centers (ASCs) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals & ambulatory surgical centers (ASCs) segment is predicted to witness the highest growth rate, due to rising patient admissions and expanding surgical procedures are increasing the demand for onsite pathology support. Many facilities are adopting digital pathology platforms to speed up diagnostic decisions. Investments in modern laboratory infrastructure are helping hospitals reduce reliance on external diagnostic centers. Adoption of AI-enabled tools is improving workflow efficiency and accuracy.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to strong healthcare infrastructure and high diagnostic testing volumes support this dominance. The region benefits from early adoption of digital pathology and AI-driven diagnostic tools. Large investments in cancer research and biomarker development further strengthen market growth. Favorable reimbursement policies encourage widespread use of advanced pathology services.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, owing to expanding healthcare systems and rising awareness of early disease diagnosis are fueling demand. Countries such as China and India are investing heavily in modern laboratory technologies. Growing incidences of cancer are accelerating the adoption of advanced pathology services. Public and private sector collaborations are improving diagnostic accessibility in emerging markets.

Key players in the market

Some of the key players in Anatomic Pathology Market include Roche Dia, Becton, Di, Thermo Fi, Hologic In, Agilent Te, PerkinElm, Danaher Co, Abbott Lab, Sakura Fin, Merck KGa, BioGenex, Cardinal H, Quest Dia, Laborator, and NeoGeno.

Key Developments:

In September 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc., a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio's pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients.

In April 2025, Thermo Fisher Scientific has introduced the Thermo Scientific(TM) Krios(TM) 5 Cryo-TEM. This next-generation, atomic-resolution platform leverages enhanced optics and AI-enabled automation to study molecular structures and interactions at a throughput and fidelity that was previously unattainable.

Products Covered:

  • Instruments
  • Consumables
  • Services

Techniques Covered:

  • Histology
  • Coagulation Tests
  • Immunohistochemistry (IHC)
  • Serology & Immunology
  • Molecular Pathology
  • Blood Routine Examination

Applications Covered:

  • Disease Diagnosis
  • Drug Discovery & Development
  • Other Applications

End Users Covered:

  • Hospitals & Ambulatory Surgical Centers (ASCs)
  • Clinical & Diagnostic Laboratories
  • Research Institutes
  • Blood Banks
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Anatomic Pathology Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
    • 5.2.1 Microtomes
    • 5.2.2 Stainers
    • 5.2.3 Tissue Processing Systems
  • 5.3 Consumables
    • 5.3.1 Reagents
    • 5.3.2 Slides & Cassettes
    • 5.3.3 Kits
  • 5.4 Services
    • 5.4.1 Histopathology Services
    • 5.4.2 Immunohistochemistry Services
    • 5.4.3 Cytopathology Services
    • 5.4.4 Digital Pathology Services

6 Global Anatomic Pathology Market, By Technique

  • 6.1 Introduction
  • 6.2 Histology
  • 6.3 Coagulation Tests
  • 6.4 Immunohistochemistry (IHC)
  • 6.5 Serology & Immunology
  • 6.6 Molecular Pathology
  • 6.7 Blood Routine Examination

7 Global Anatomic Pathology Market, By Application

  • 7.1 Introduction
  • 7.2 Disease Diagnosis
    • 7.2.1 Oncology
    • 7.2.2 Infectious Diseases
    • 7.2.3 Chronic Conditions
  • 7.3 Drug Discovery & Development
  • 7.4 Other Applications

8 Global Anatomic Pathology Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Ambulatory Surgical Centers (ASCs)
  • 8.3 Clinical & Diagnostic Laboratories
  • 8.4 Research Institutes
  • 8.5 Blood Banks
  • 8.6 Other End Users

9 Global Anatomic Pathology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Roche Diagnostics
  • 11.2 Becton, Dickinson and Company (BD)
  • 11.3 Thermo Fisher Scientific
  • 11.4 Hologic Inc.
  • 11.5 Agilent Technologies
  • 11.6 PerkinElmer
  • 11.7 Danaher Corporation
  • 11.8 Abbott Laboratories
  • 11.9 Sakura Finetek Japan
  • 11.10 Merck KGaA
  • 11.11 BioGenex Laboratories
  • 11.12 Cardinal Health
  • 11.13 Quest Diagnostics
  • 11.14 Laboratory Corporation of America Holdings
  • 11.15 NeoGenomics Laboratories

List of Tables

  • Table 1 Global Anatomic Pathology Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Anatomic Pathology Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Anatomic Pathology Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Anatomic Pathology Market Outlook, By Microtomes (2024-2032) ($MN)
  • Table 5 Global Anatomic Pathology Market Outlook, By Stainers (2024-2032) ($MN)
  • Table 6 Global Anatomic Pathology Market Outlook, By Tissue Processing Systems (2024-2032) ($MN)
  • Table 7 Global Anatomic Pathology Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 8 Global Anatomic Pathology Market Outlook, By Reagents (2024-2032) ($MN)
  • Table 9 Global Anatomic Pathology Market Outlook, By Slides & Cassettes (2024-2032) ($MN)
  • Table 10 Global Anatomic Pathology Market Outlook, By Kits (2024-2032) ($MN)
  • Table 11 Global Anatomic Pathology Market Outlook, By Services (2024-2032) ($MN)
  • Table 12 Global Anatomic Pathology Market Outlook, By Histopathology Services (2024-2032) ($MN)
  • Table 13 Global Anatomic Pathology Market Outlook, By Immunohistochemistry Services (2024-2032) ($MN)
  • Table 14 Global Anatomic Pathology Market Outlook, By Cytopathology Services (2024-2032) ($MN)
  • Table 15 Global Anatomic Pathology Market Outlook, By Digital Pathology Services (2024-2032) ($MN)
  • Table 16 Global Anatomic Pathology Market Outlook, By Technique (2024-2032) ($MN)
  • Table 17 Global Anatomic Pathology Market Outlook, By Histology (2024-2032) ($MN)
  • Table 18 Global Anatomic Pathology Market Outlook, By Coagulation Tests (2024-2032) ($MN)
  • Table 19 Global Anatomic Pathology Market Outlook, By Immunohistochemistry (IHC) (2024-2032) ($MN)
  • Table 20 Global Anatomic Pathology Market Outlook, By Serology & Immunology (2024-2032) ($MN)
  • Table 21 Global Anatomic Pathology Market Outlook, By Molecular Pathology (2024-2032) ($MN)
  • Table 22 Global Anatomic Pathology Market Outlook, By Blood Routine Examination (2024-2032) ($MN)
  • Table 23 Global Anatomic Pathology Market Outlook, By Application (2024-2032) ($MN)
  • Table 24 Global Anatomic Pathology Market Outlook, By Disease Diagnosis (2024-2032) ($MN)
  • Table 25 Global Anatomic Pathology Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 26 Global Anatomic Pathology Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 27 Global Anatomic Pathology Market Outlook, By Chronic Conditions (2024-2032) ($MN)
  • Table 28 Global Anatomic Pathology Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
  • Table 29 Global Anatomic Pathology Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 30 Global Anatomic Pathology Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Anatomic Pathology Market Outlook, By Hospitals & Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 32 Global Anatomic Pathology Market Outlook, By Clinical & Diagnostic Laboratories (2024-2032) ($MN)
  • Table 33 Global Anatomic Pathology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 34 Global Anatomic Pathology Market Outlook, By Blood Banks (2024-2032) ($MN)
  • Table 35 Global Anatomic Pathology Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.